中华皮肤科杂志 ›› 2005, Vol. 38 ›› Issue (8): 470-473.

• 论著 • 上一篇    下一篇

甲真菌病临床评分指数指导伊曲康唑和特比萘芬治疗甲真菌病的疗效对比研究

胡燕, 杨莉佳, 戴迅毅, 张海平, 魏聆, 华海康, 戚稼, 孙慧, 郑渊, 蒋屏东   

  1. 南京医科大学附属无锡市第二人民医院皮肤科 无锡 214002
  • 收稿日期:2004-12-07 发布日期:2005-08-15

Therapeutic Effects of Itraconazole and Terbinafine for the Treatment of Onychomycosis Evaluated with Scoring Clinical Index

HU Yan, YANG Li-jia, DAI Xun-yi, ZHANG Hai-ping, WEI Ling, HUA Hai-kang, QI Jia, SUN Hui, ZHENG Yuan, JIANG Ping-dong   

  1. Department of Dermatology, The Second Affiliated People's Hospital of Wuxi, Nanjing Medical University, Wuxi 214002, China
  • Received:2004-12-07 Published:2005-08-15

PDF

221

赞

摘要： 目的 评价甲真菌病临床评分指数(SCIO)指导伊曲康唑冲击和特比萘芬连续疗法治疗甲真菌病的疗效、安全性及费用疗效比.方法 制定SCIO评分体系,对200例甲真菌病患者的靶甲进行SCIO评分,根据SCIO积分范围随机分为2组,分别给予伊曲康唑冲击治疗和特比萘芬连续治疗.结果 2种药物均有较好的抗真菌疗效.伊曲康唑组和特比萘芬组近、中、远期临床和真菌学疗效差异均无统计学意义(P>0.05),伊曲康唑组远期复发率4.26%,特比萘芬组尚未观察到复发病例.伊曲康唑组不良事件发生率为23%,特比萘芬组为21%(P>0.05).Ⅱ度患者伊曲康唑组费用疗效比低于特比萘芬组,Ⅲ度和Ⅳ度患者特比萘芬组费用疗效比低于伊曲康唑组,但差异均无统计学意义(P>0.05).结论 SCIO具有一定的科学性和实用性,指导伊曲康唑冲击和特比萘芬连续疗法治疗甲真菌病显示同样有效且安全.

关键词: 甲癣, 伊曲康唑, 特比萘芬, 临床评分指数

Abstract: Objective To assess the efficacy,safety and cost-effectiveness of itraconazole and terbinafine for the treatment of onychomycosis,evaluated by the scoring clinical index of onychomycosis (SCIO).Methods The system of SCIO was established and applied to evaluate 200 patients with onychomycosis,who were randomly divided into two treatment groups,one with intermittent pulse itraconazole (Group Ⅰ) and continuous terbinafine (Group T).The therapeutic responses were assessed based on the scores of the target nails with SCIO system.Results Good antifungal effects were achieved in both groups.The short-,medium-,and long-term clinical and mycological cure rates were not significantly different in the two groups (P>0.05).The long-term recurrence rates were 4.26% in Group Ⅰ,and 0 in Group T.Adverse reactions were observed in 23% of Group Ⅰ,and 21% in Group T(P>0.05).Treatment with itraconazole seemed more cost-effective in degree Ⅱ patients,and less cost-effective in degree Ⅲ and Ⅳ patients,than that with terbinafine,however,the differences were not statistically significant (P>0.05).Conclusions The SCIO system is practical to assess the therapeutic effects of itraconazole and terbinafine for patients with onychomycosis.Treatment of onychomycosis with the two drugs is equally effective and safe.

Key words: Onychomycosis, Itraconazole, Terbinafine, Scoring clinical index